Sartorius Vz. in Pivotal Point Check: Order Intake Rises by 21.5% in Q4 and Signals Recovery in 2025!

With the 2024 numbers, Sartorius shares briefly soared by 16%. The customers of the laboratory and pharmaceutical supplier have reached their target inventory levels and are returning to a normal order level. For the fiscal year 2025, the management expects a continued recovery in demand. The life science company was able to establish itself in the challenging industry environment in 2024 according to preliminary figures published on January 28, 2025. Sartorius maintained its strong market position and high profitability, achieving revenue...